Opinion of the Transparency Council – bosutinib and nilotinib
At its meeting on 19 May 2025, the Transparency Council adopted opinion No. 86/2025on the transfer of medicinal products containing the active substances bosutinib and nilotinib from the B.14 drug program. “Treatment of patients with chronic myeloid leukemia (ICD-10: C92.1)” to the catalog of reimbursed drugs in chemotherapy